NeuroSonic

What NeuroSonic does

NeuroSonic is a privately held medical device company developing a handheld, non-invasive device that performs carotid artery blood flow analysis to enable rapid stroke risk assessment at the point of care. The device is paired with a companion mobile application that displays waveform data and instant risk insights to clinicians and patients, and is designed to integrate with existing hospital systems. The product is positioned as a triage tool to help clinicians determine when traditional imaging is warranted, rather than as a replacement for ultrasound or other imaging modalities.

The company sells (or intends to sell) its hardware to licensed healthcare professionals in hospitals and clinical settings. Pricing is not publicly disclosed and the company is pre-commercial: its own website states it is "currently undergoing clinical validation and regulatory review" with availability varying by location and regulatory status. The founding team consists of three people — Mike Ryan (Co-founder & CEO), Matthew Campbell (Co-founder & CPO), and Alan Solinski (Founding Engineer) — and total headcount is reported at 1-10.

NeuroSonic has assembled a notable network of clinical validation partners including Stanford Healthcare, MGB, Henry Ford Healthcare, Providence Medical System, and University Clinical Center Gdansk. It is backed by multiple investors including Emergent Ventures, Entrepreneurs First, Transpose Platform, Detroit Venture Partners, Long Journey Ventures, and Anorak Ventures. In June 2026 the company was selected for the inaugural cohort of the MSWA & Founders Factory MS & Neurological Care Accelerator in Western Australia, extending its geographic footprint and broadening its clinical focus toward multiple sclerosis and broader neurological care.

Name

NeuroSonic

Legal name

NeuroSonic

Website

https://neuro-sonic.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Short description

NeuroSonic is a private pre-clinical medical device company developing a handheld, non-invasive carotid artery blood flow analyzer paired with a mobile app to help clinicians perform rapid stroke risk assessment at the point of care, targeting licensed healthcare professionals in hospitals and clinical settings.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industry

Stroke & Vascular Neurology (HLAKAIAG)

Keywords

• Stroke risk assessment
• Vascular health screening
• Medical diagnostic devices
• Carotid artery imaging
• Preventive cardiac health

Headquarters

HQ city

Michigan Center

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Sale of handheld medical devices to healthcare institutions and clinical settings. The device is complemented by a mobile application that displays assessment results, suggesting potential for recurring software or service components.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

NeuroSonic develops a handheld, non-invasive medical device that enables clinicians to perform rapid carotid artery blood flow assessment for stroke risk evaluation. The device is positioned on each side of the neck and provides instant vascular insights, with results delivered through a companion mobile application that displays waveform data and risk assessments to clinicians and patients.

Product overview

NeuroSonic offers a single unified product combining a handheld medical device with a companion mobile application. The device performs carotid artery assessment by analyzing blood flow when positioned on the neck, while the app delivers instant risk insights and raw waveform data to both clinicians and patients, enabling rapid stroke risk evaluation at the point of care.

Differentiator

Problem solved

Functional benefit

Products and services

• NeuroSonic Handheld Stroke Risk Assessment Device

Quantifiable outcome

• 80% of strokes are preventable with early assessment and intervention

Named customers5 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• MSWAcoreStrategic or Co-development Partner · 1 June 2026Western Australia's leading MS and neurological care organization that launched the world's first MS & Neurological Care Accelerator in partnership with Founders Factory. NeuroSonic was selected as one of five startups for the inaugural cohort, gaining access to MSWA's clinical network and community of people living with neurological conditions for technology validation and piloting.
• Founders FactorycoreStrategic or Co-development Partner · 1 June 2026Global venture capital and startup accelerator platform that partnered with MSWA to launch the world's first MS & Neurological Care Accelerator. NeuroSonic was selected for the inaugural cohort to access clinical validation support.
• Stanford HealthcarecoreStrategic or Co-development PartnerMajor academic medical center partnership for clinical validation and deployment of NeuroSonic's stroke risk assessment technology in real-world care environments.
• MGBcoreStrategic or Co-development PartnerHealthcare system partner for clinical validation and potential deployment of NeuroSonic's technology.
• Henry Ford HealthcarecoreStrategic or Co-development PartnerHealthcare system partner for clinical validation and deployment of stroke risk assessment technology.
• Providence Medical SystemcoreStrategic or Co-development PartnerHealthcare system partner providing clinical validation and deployment environment for NeuroSonic's technology.
• University Clinical Center GdanskminorStrategic or Co-development PartnerInternational academic medical center partner for clinical validation of NeuroSonic's stroke assessment technology.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• Viz.ai: Viz.ai applies AI to stroke detection and triage workflows across hospital networks. Although it uses imaging AI rather than a handheld blood-flow device, it competes for the same clinical priority — faster stroke decision-making — and the same hospital customers.
• RapidAI: RapidAI provides AI-powered analysis of stroke imaging (CT perfusion, CT angiography) to accelerate triage and treatment. It is an adjacent emerging player addressing the same stroke-time-to-treatment problem from an imaging-software angle rather than a screening-device angle.

Broad incumbents

• Canon Medical Systems: Canon Medical Systems is a global imaging incumbent with ultrasound and vascular imaging products. As a broad industry player it competes in the same clinical workflows NeuroSonic targets, even though it does not focus on handheld carotid screening.
• Philips: Philips is a global medical imaging incumbent with its Lumify handheld ultrasound system and a deep cardiology/vascular ultrasound franchise. It offers overlapping capabilities and can leverage its enterprise hospital relationships against NeuroSonic.
• Siemens Healthineers: Siemens Healthineers is a global imaging incumbent with ultrasound, CT, and MR capabilities that compete in the vascular and stroke imaging category NeuroSonic is positioning against. Its broad portfolio and clinical evidence base make it a key indirect competitor.
• GE HealthCare: GE HealthCare is a global incumbent in medical imaging with the Vscan line of handheld ultrasound products. It competes broadly in the carotid and vascular ultrasound category NeuroSonic targets and has the scale, channel, and installed base to influence category adoption.

Direct peers

• NovaSignal: NovaSignal develops AI-guided transcranial Doppler technology for neurovascular assessment, including stroke detection and monitoring. It overlaps directly with NeuroSonic's neurovascular, point-of-care stroke-risk screening positioning.
• Butterfly Network: Butterfly Network makes handheld, AI-enabled point-of-care ultrasound devices used across multiple clinical workflows including vascular assessment. It is the closest direct peer in form factor, target buyer (clinicians at point of care), and use case overlap (carotid and vascular screening).
• Exo Imaging: Exo Imaging builds handheld ultrasound platforms with AI software for use at the point of care. Its handheld hardware-plus-AI-software model closely mirrors NeuroSonic's device-plus-app architecture and clinician-targeted go-to-market.
• Active Medical Inc: Active Medical Inc manufactures handheld and portable ultrasound systems used at the point of care, including for vascular applications. It is a direct peer in form factor, clinician-targeted positioning, and core use case overlap with NeuroSonic's handheld stroke-risk device.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/neuro-sonic

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroSonic